In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.